ES2196171T3 - Agentes antitumorales de tioxantenona liofilizada. - Google Patents

Agentes antitumorales de tioxantenona liofilizada.

Info

Publication number
ES2196171T3
ES2196171T3 ES96929491T ES96929491T ES2196171T3 ES 2196171 T3 ES2196171 T3 ES 2196171T3 ES 96929491 T ES96929491 T ES 96929491T ES 96929491 T ES96929491 T ES 96929491T ES 2196171 T3 ES2196171 T3 ES 2196171T3
Authority
ES
Spain
Prior art keywords
liofilized
tioxantenone
food agents
food
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96929491T
Other languages
English (en)
Inventor
Stephen Brown
Gurdial Singh Sandhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Synthelabo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo Inc filed Critical Sanofi Synthelabo Inc
Application granted granted Critical
Publication of ES2196171T3 publication Critical patent/ES2196171T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

SE REVELAN FORMULACIONES LIOFILIZADAS RECONSTITUIDAS PARA EL TRATAMIENTO DE TUMORES DE MAMIFEROS, QUE COMPRENDEN UN AGENTE ANTITUMORAL COMBINADO CON MANNITOL O SACAROSA COMO ESTABILIZADOR, EN UN TAMPON DE LACTATO.
ES96929491T 1995-09-18 1996-09-12 Agentes antitumorales de tioxantenona liofilizada. Expired - Lifetime ES2196171T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/529,934 US5665760A (en) 1995-09-18 1995-09-18 Lyophilized thioxanthenone antitumor agents

Publications (1)

Publication Number Publication Date
ES2196171T3 true ES2196171T3 (es) 2003-12-16

Family

ID=24111801

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96929491T Expired - Lifetime ES2196171T3 (es) 1995-09-18 1996-09-12 Agentes antitumorales de tioxantenona liofilizada.

Country Status (19)

Country Link
US (1) US5665760A (es)
EP (1) EP0917458B1 (es)
JP (1) JP2001503374A (es)
KR (1) KR100475385B1 (es)
CN (1) CN1178651C (es)
AT (1) ATE235888T1 (es)
AU (1) AU716782B2 (es)
CA (1) CA2232444A1 (es)
CZ (1) CZ293433B6 (es)
DE (1) DE69627209T2 (es)
DK (1) DK0917458T3 (es)
ES (1) ES2196171T3 (es)
HU (1) HUP9900246A3 (es)
NO (1) NO320367B1 (es)
NZ (1) NZ316609A (es)
PL (1) PL185164B1 (es)
PT (1) PT917458E (es)
RU (1) RU2157189C2 (es)
WO (1) WO1997010809A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
GB0115893D0 (en) * 2001-06-28 2001-08-22 Sanofi Synthelabo Formulations
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
JP2007526329A (ja) * 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
AU2006329849A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582851A (en) * 1984-02-06 1986-04-15 Warner-Lambert Company Anti-bacterial 1,4-aminoalkylamino-9H-thioxanthen-9-one derivatives, compositions, and method of use therefor
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
AU642596B2 (en) * 1991-06-10 1993-10-21 Sanofi-Synthelabo Thioxanthenone antitumor agents
US5091410A (en) * 1991-06-10 1992-02-25 Sterling Winthrop Inc. Thioxanthenone antitumor agents

Also Published As

Publication number Publication date
KR100475385B1 (ko) 2006-03-23
JP2001503374A (ja) 2001-03-13
KR19990045741A (ko) 1999-06-25
HUP9900246A2 (hu) 2001-04-28
PL185164B1 (pl) 2003-03-31
NO320367B1 (no) 2005-11-28
WO1997010809A1 (en) 1997-03-27
DE69627209T2 (de) 2004-02-19
NO981205L (no) 1998-05-15
CZ293433B6 (cs) 2004-04-14
DE69627209D1 (en) 2003-05-08
CN1201387A (zh) 1998-12-09
PT917458E (pt) 2003-08-29
RU2157189C2 (ru) 2000-10-10
DK0917458T3 (da) 2003-07-28
EP0917458B1 (en) 2003-04-02
MX9802143A (es) 1998-05-31
NO981205D0 (no) 1998-03-17
PL325603A1 (en) 1998-08-03
CZ79998A3 (cs) 1998-08-12
ATE235888T1 (de) 2003-04-15
US5665760A (en) 1997-09-09
CA2232444A1 (en) 1997-03-27
HK1016891A1 (zh) 1999-11-12
EP0917458A1 (en) 1999-05-26
HUP9900246A3 (en) 2002-12-28
CN1178651C (zh) 2004-12-08
AU716782B2 (en) 2000-03-09
AU6888096A (en) 1997-04-09
NZ316609A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
ES2095017T3 (es) Composicion cosmetica o farmaceutica que comprende en asociacion una peroxidasa y un agente antioxigeno singulete.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2137372T3 (es) Solucion antifungica para las uñas.
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
ES2159591T3 (es) Composicion de liberacion controlada.
ES2171971T3 (es) Producto limpiador y de tratamiento con almidon.
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
GT199800037A (es) Combinaciones para diabetes de sulfonilurea - glitazona.
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
AR241802A1 (es) Una composicion para la determinacion de iones en fluidos.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
AR001982A1 (es) Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AR020455A1 (es) Composicion insecticida
AR023511A1 (es) Composicion que comprende (s) y (r) 5-amino-3-ciano-1-(2,6-dicloro-4-trifluorometilfenil)-4-trifluoro-metilsulfinilpirazol, dichos compuestos aislados y usos de los mismos como plaguicida
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo